Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs

被引:65
作者
Zunino, F [1 ]
Pratesi, G [1 ]
Perego, P [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy
关键词
anthracyclines; disaccharides; antitumor therapy;
D O I
10.1016/S0006-2952(01)00522-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The sugar moiety is an essential component of anthracycline antibiotics for their topoisomerase poisoning activity and antitumor efficacy. Since the sugar interacts with the minor groove, modifications in this moiety could enhance the recognition potential of the drug at the target level. Based on this hypothesis, novel anthracyclines, disaccharides lacking the amino group in the first (aglycone-linked) sugar, were designed. The 3'-amino group in the first sugar was replaced by an hydroxyl group, and the second sugar residue was bound to the first sugar via an alpha (1-4) linkage. The cytotoxic and antitumor activities of disaccharide analogs of idarubicin were critically dependent on the optimal (axial) orientation of the second sugar residue. Although configurational requirements of the sugar moiety for optimal drug activity support a critical role of the external (non-intercalating) drug domains in the interaction of anthracyclines with the DNA-topoisomerase (ternary complex), the antitumor efficacy of disaccharide analogs is not fully explained by effects mediated by the nuclear enzyme target. The development of this novel disaccharide series may provide insights fur a rational synthesis of anthracycline analogs with improved pharmacological profile. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:933 / 938
页数:6
相关论文
共 37 条
[1]   New anthracycline disaccharides. Synthesis of L-daunosaminyl-alpha(1->4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-alpha(1->4)-2-deoxy-L-fucosyl daunorubicin analogues [J].
Animati, F ;
Arcamone, F ;
Berettoni, M ;
Cipollone, A ;
Franciotti, M ;
Lombardi, P .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1996, (12) :1327-1329
[2]  
Animati F, 1996, MOL PHARMACOL, V50, P603
[3]   New developments in antitumor anthracyclines [J].
Arcamone, F ;
Animati, F ;
Capranico, G ;
Lombardi, P ;
Pratesi, G ;
Manzini, S ;
Supino, R ;
Zunino, F .
PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :117-124
[4]   Doxorubicin disaccharide analogue: Apoptosis-related improvement of efficacy in vivo [J].
Arcamone, F ;
Animati, F ;
Berettoni, M ;
Bigioni, M ;
Capranico, G ;
Casazza, AM ;
Caserini, C ;
Cipollone, A ;
DeCesare, M ;
Franciotti, M ;
Lombardi, P ;
Madami, A ;
Manzini, S ;
Monteagudo, E ;
Polizzi, D ;
Pratesi, G ;
Righetti, SC ;
Salvatore, C ;
Supino, R ;
Zunino, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (16) :1217-1223
[5]  
Arcamone F, 1998, CURR MED CHEM, V5, P391
[6]   Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides [J].
Arcamone, F ;
Animati, F ;
Bigioni, M ;
Capranico, G ;
Caserini, C ;
Cipollone, A ;
De Cesare, M ;
Ettorre, A ;
Guano, F ;
Manzini, S ;
Monteagudo, E ;
Pratesi, G ;
Salvatore, C ;
Supino, R ;
Zunino, F .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (10) :1133-1139
[7]  
ARCAMONE F, 1981, MED CHEM SERIES, V17, P196
[8]  
Binaschi M, 1998, CANCER RES, V58, P1886
[9]  
CAPRANICO G, 1994, MOL PHARMACOL, V45, P908
[10]  
CAPRANICO G, 1995, CANCER RES, V55, P312